Edaravone is under clinical development by Treeway and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Edaravone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Edaravone overview

Edaravone (TW-001) is under development for the treatment of amyotrophic lateral sclerosis and Alzheimer's Disease. The drug candidate is administered through oral route.The drug candidate is a neuroprotective agent. It targets free radicals.

Treeway overview

Treeway is a biotechnology company that develops drugs for the treatment of amyotrophic lateral sclerosis (ALS). The company’s clinical programs include TW001, an oral formulation of edaravone, which protects against neuronal apoptosis and oxidative stress. Its pre clinical program TW002, is an AAV5-GDNF gene therapy that offers an innovative administration modality for clinical use. Treeway’s discovery research activities include project minE, motor neuron signalling, the immune system, and others. The company collaborates with research and clinical institutes for performing clinical trials in ALS. Treeway is headquartered in Tilburg, Noord-Brabant, the Netherlands.

For a complete picture of Edaravone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.